


Secondary Intelligence™

Safety issues account for about a quarter of the attrition in drug projects. If it is a result of the primary pharmacology, you have to either drop the target entirely or manage the risk. However, if this arises from off-target activity, you have the additional option to dial this out and avoid the associated adverse events (AEs). This is the discipline of Secondary Pharmacology, the focus of Certara's new in silico technology.





SECONDARY INTELLIGENCE: PREDICTIVE TECHNOLOGY FOR IMPROVING SAFETY PROFILES

Secondary Intelligence™ assembles, curates and visualizes all secondary pharmacology analyses, providing key information on potential AEs, quantitatively rating each compound as to its likelihood of causing off-target safety issues that could impact clinical progress. The first module in Certara's ToxStudio™ integrated modelling & simulation platform for safety pharmacology, toxicology and patient safety, *Secondary Intelligence™* is the only tool available to address this translational challenge.


- Secondary Intelligence assembles curated, organised information for a compound's secondary pharmacology readouts and analysis in one place.
- It provides up-to-date literature-based information on the expected side effects of a given compound as it engages with a particular off-target receptor in clinical use.
- This data enables virtual in vitro in vivo extrapolation (IVIVE).
- It rates each compound with a 'low', 'intermediate' or 'high' likelihood of causing AEs at the off-target receptor in clinical use, based on quantitative analysis of clinically used drugs that specifically target that receptor, and on its predicted plasma Cmax
- Secondary Intelligence will integrate with Certara's Simcyp® PBPK software platform, which is crucial for the assessment of the relevant tissue concentrations.

Like radar, Secondary Pharmacology provides early alerts and allows you to decide on your next move.





Secondary Intelligence software identifies the key safety/tox information about each receptor, allowing you to focus on how a test compound interacts with that receptor. It can address safety performance against multiple receptors. Secondary Intelligence ranks the likelihood of each off-target interaction during clinical use, color-coding in red, amber or green.



Secondary Intelligence prioritises “receptor interactions of concern” in a variety of data representations, and ranks compounds against each other to make quantitatively based decisions as to which compounds to progress.

About Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

For more information visit www.certara.com or email sales@certara.com.